2017 journal article

Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs


By: B. Hammerberg n & S. Eguiluz-Hernandez n

MeSH headings : Animals; Antibodies, Anti-Idiotypic / administration & dosage; Antibodies, Anti-Idiotypic / adverse effects; Antibodies, Anti-Idiotypic / immunology; Antibodies, Anti-Idiotypic / therapeutic use; Antibodies, Monoclonal / adverse effects; Antibodies, Monoclonal / immunology; Antibodies, Monoclonal / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / immunology; Dogs; Epitopes; Female; Immunoglobulin E / immunology; Immunologic Factors / administration & dosage; Immunologic Factors / adverse effects; Immunologic Factors / immunology; Immunologic Factors / therapeutic use; Injections, Subcutaneous; Male
TL;DR: A single injection of monomeric, pegylated scFv with high affinity for dog IgE was demonstrated to be safe and marked reduction in IgE‐bearing lymphocytes and granulocytes accompanied by reduced “free” plasma IgE level in two of four dogs is analogous to omalizumab in humans. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (OpenAlex)
Source: Web Of Science
Added: August 6, 2018

BackgroundThe therapeutic monoclonal antibody omalizumab that is specific for IgE has proven to be an effective addition to the treatment of allergic disease in humans.